Your browser doesn't support javascript.
loading
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial.
Carreira, Suzanne; Porta, Nuria; Arce-Gallego, Sara; Seed, George; Llop-Guevara, Alba; Bianchini, Diletta; Rescigno, Pasquale; Paschalis, Alec; Bertan, Claudia; Baker, Chloe; Goodall, Jane; Miranda, Susana; Riisnaes, Ruth; Figueiredo, Ines; Ferreira, Ana; Pereira, Rita; Crespo, Mateus; Gurel, Bora; Nava Rodrigues, Daniel; Pettitt, Stephen J; Yuan, Wei; Serra, Violeta; Rekowski, Jan; Lord, Christopher J; Hall, Emma; Mateo, Joaquin; de Bono, Johann S.
Afiliação
  • Carreira S; The Institute of Cancer Research, London, United Kingdom.
  • Porta N; The Institute of Cancer Research, London, United Kingdom.
  • Arce-Gallego S; Vall d'Hebron Institute of Oncology (VHIO) and Vall d'Hebron University Hospital, Barcelona, Spain.
  • Seed G; The Institute of Cancer Research, London, United Kingdom.
  • Llop-Guevara A; Vall d'Hebron Institute of Oncology (VHIO) and Vall d'Hebron University Hospital, Barcelona, Spain.
  • Bianchini D; The Institute of Cancer Research, London, United Kingdom.
  • Rescigno P; The Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Paschalis A; The Institute of Cancer Research, London, United Kingdom.
  • Bertan C; The Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Baker C; The Institute of Cancer Research, London, United Kingdom.
  • Goodall J; The Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Miranda S; The Institute of Cancer Research, London, United Kingdom.
  • Riisnaes R; The Institute of Cancer Research, London, United Kingdom.
  • Figueiredo I; The Institute of Cancer Research, London, United Kingdom.
  • Ferreira A; The Institute of Cancer Research, London, United Kingdom.
  • Pereira R; The Institute of Cancer Research, London, United Kingdom.
  • Crespo M; The Institute of Cancer Research, London, United Kingdom.
  • Gurel B; The Institute of Cancer Research, London, United Kingdom.
  • Nava Rodrigues D; The Institute of Cancer Research, London, United Kingdom.
  • Pettitt SJ; The Institute of Cancer Research, London, United Kingdom.
  • Yuan W; The Institute of Cancer Research, London, United Kingdom.
  • Serra V; The Institute of Cancer Research, London, United Kingdom.
  • Rekowski J; The Institute of Cancer Research, London, United Kingdom.
  • Lord CJ; The Institute of Cancer Research, London, United Kingdom.
  • Hall E; Vall d'Hebron Institute of Oncology (VHIO) and Vall d'Hebron University Hospital, Barcelona, Spain.
  • Mateo J; The Institute of Cancer Research, London, United Kingdom.
  • de Bono JS; The Institute of Cancer Research, London, United Kingdom.
Cancer Discov ; 11(11): 2812-2827, 2021 11.
Article em En | MEDLINE | ID: mdl-34045297
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Antineoplásicos Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Antineoplásicos Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article